DB
FTH

Dmitry Balyasny’s Faeth Therapeutics FTH Stock Holding History

Dmitry Balyasny’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.1M Buy
1,042,198
+1,025,993
+6,331% +$23.7M 0.03% 598
2026
Q1 		$511K Buy
+16,205
New +$324K ﹤0.01% 2359
2021
Q2 		– Sell
-1,380
Closed -$401K – 2317
2021
Q1 		$401K Buy
+1,380
New +$462K ﹤0.01% 1451

Other funds holding FTH

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Dmitry Balyasny's FTH Position: Q2 2026 in Review

Dmitry Balyasny increased its Faeth Therapeutics (FTH) stake by 6,331% in Q2 2026, buying an estimated $23.7M and bringing the position to 1,042,198 shares worth $26.1M. The position accounts for 0.03% of the portfolio, ranked #598.

Dmitry Balyasny first reported a position in FTH in Q1 2021 and has held it in 3 quarters since. 45 funds tracked by Wall St. Rank hold FTH as of Q2 2026.

  • Dmitry Balyasny held 1,042,198 shares of Faeth Therapeutics worth $26.1M as of Q2 2026.
  • Dmitry Balyasny bought 1,025,993 Faeth Therapeutics shares in Q2 2026, an estimated $23.7M.
  • Faeth Therapeutics made up 0.03% of Dmitry Balyasny's portfolio in Q2 2026, its #598 holding.
  • Dmitry Balyasny first reported a position in Faeth Therapeutics in Q1 2021 and has held it in 3 quarters since.
  • 45 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.